Cardiology

PCSK9 inhibition with bococizumab yields mixed results

In a clinical program that was terminated early, the experimental PCSK9 inhibitor bococizumab, when given on top of effective statin therapy, had widely varying effects on LDL cholesterol levels and had no benefit on cardiovascular ...

Cardiology

Researchers study a new way to lower LDL cholesterol

In a paper published in Biochemical Pharmacology, Saint Louis University researchers examined the way a nuclear receptor called REV-ERB is involved in regulating cholesterol metabolism. Their findings suggest that drugs targeting ...

Cardiology

Most younger adults with high LDL-C levels do not take a statin

Despite recommendations, less than 45 percent of adults younger than 40 years with an elevated low-density lipoprotein cholesterol (LDL-C) level of 190 mg/dL or greater receive a prescription for a statin, according to a ...

Diabetes

Higher oxidative stress linked to metabolic syndrome

(HealthDay)—Oxidized low-density lipoprotein (ox-LDL) as a proxy for oxidative stress is associated with metabolic syndrome (MetS) and its components, according to a study published online Dec. 19 in Diabetes.

page 24 from 38